TXG

10x Genomics, Inc.

TXG · CIK 1770787 · Annual (10-K) · Last 7 years

Financial Trends

Revenue$643M
20192025
Net Income−$44M
20192025
Operating CF$136M
20192025
Free Cash Flow$130M
20192025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕
Revenue$0.6B$0.6B$0.6B$0.5B$0.5B$0.3B$0.1B
Cost of Revenue$0.2B$0.2B$0.2B$0.1B$0.1B$0.1B$0.1B
Gross Profit$0.4B$0.4B$0.4B$0.4B$0.4B$0.2B$0.1B
R&D Expense———————
SG&A Expense$0.3B$0.3B$0.3B$0.3B$0.3B$0.2B$0.1B
Operating Income$-0.1B$-0.2B$-0.3B$-0.2B$-0.1B$-0.5B$-0.0B
Net Income$-0.0B$-0.2B$-0.3B$-0.2B$-0.1B$-0.5B$-0.0B
EPS (Basic)$-0.35$-1.52$-2.18$-1.46$-0.53——
EPS (Diluted)$-0.35$-1.52$-2.18$-1.46$-0.53——

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕
Total Assets$1.0B$0.9B$1.0B$1.0B$1.0B$0.9B$0.6B
Current Assets$0.7B$0.6B$0.6B$0.6B$0.7B$0.8B$0.5B
Cash & Equivalents—$0.3B$0.4B$0.2B$0.6B$0.7B$0.4B
Total Liabilities$0.2B$0.2B$0.2B$0.2B$0.2B$0.2B$0.2B
Current Liabilities$0.2B$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B
Stockholders' Equity$0.8B$0.7B$0.7B$0.8B$0.8B$0.7B$0.4B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕
Operating Cash Flow$0.1B$0.0B$-0.0B$-0.0B$-0.0B$-0.2B$0.0B
Investing Cash Flow$-0.0B$-0.0B$0.1B$-0.4B$-0.1B$-0.0B$-0.0B
Capital Expenditures$0.0B$0.0B$0.0B$0.1B$0.1B$0.0B$0.0B
Financing Cash Flow$0.0B$0.0B$0.0B$0.0B$0.0B$0.5B$0.4B
← Companies